Dermatology · Webster, TX
Dermatology and skin studies in Webster, TX
7 recruiting studies have a site in Webster.
7 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Oruka Therapeutics, Inc.
- Location
- Webster, TX + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Pfizer
- Location
- Webster, TX + 28 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Novartis Pharmaceuticals
- Location
- Webster, TX + 20 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Incyte Corporation
- Location
- Webster, TX + 73 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
Vanda Pharmaceuticals
- Location
- Webster, TX + 9 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 4
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice…
Eli Lilly and Company
- Location
- Webster, TX + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
Oneness Biotech Co., Ltd.
- Location
- Webster, TX + 5 other US sites
- Eligibility basics
- Ages 18–65
Who these studies look for
Most require an active, diagnosed skin condition of a certain severity and a pause on some current treatments before starting.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.